Status:
RECRUITING
AI-powered Early Detection for Pancreatic Cancer Via Non-contrast CT in Opportunistic Screening Cohort
Lead Sponsor:
Changhai Hospital
Collaborating Sponsors:
Yinzhou Hospital Affiliated to Medical School of Ningbo University
The Second Affiliated Hospital of Jiaxing University
Conditions:
Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma
Eligibility:
All Genders
18+ years
Brief Summary
Pancreatic ductal adenocarcinoma (PDAC) remains a therapeutic challenge with 5-year survival rates of 13%, primarily attributable to advanced-stage diagnosis (AJCC Stage III/IV in \>80% of cases). Thi...
Detailed Description
PDAC is projected to become the second-leading cause of cancer mortality by 2030, with stage-specific survival disparities reaching 83.7% for stage IA versus 2.9% for stage IV disease. This dramatic s...
Eligibility Criteria
Inclusion Criteria
1. Individuals undergoing routine non-contrast chest and/or abdominal CT scans for non-pancreatic indications.
Exclusion Criteria
- History of pancreatic cancer;
- History of thoracic or abdominal surgery;
- Acute pancreatitis within 6 months;
- Patients referred for evaluation of suspected or confirmed pancreatic cancer.
Key Trial Info
Start Date :
August 3 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2030
Estimated Enrollment :
5000 Patients enrolled
Trial Details
Trial ID
NCT06638866
Start Date
August 3 2024
End Date
December 31 2030
Last Update
March 19 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Changhai Hospital
Shanghai, Shanghai Municipality, China, 200433
2
Second Affiliated Hospital of Jiaxing University
Jiaxing, Zhejiang, China, 314000
3
Yinzhou Hospital Affiliated to Medical School of Ningbo University
Ningbo, Zhejiang, China, 315100